What’s Next for Abiomed Inc (NASDAQ:ABMD) After Having Less Shares Shorted?

March 16, 2018 - By Linda Rogers

 What's Next for Abiomed Inc (NASDAQ:ABMD) After Having Less Shares Shorted?

Investors sentiment decreased to 1.3 in Q3 2017. Its down 0.13, from 1.43 in 2017Q2. It turned negative, as 27 investors sold ABIOMED, Inc. shares while 89 reduced holdings. 55 funds opened positions while 96 raised stakes. 38.51 million shares or 1.21% less from 38.99 million shares in 2017Q2 were reported.
Virginia-based Palladium Prns Lc has invested 0.02% in ABIOMED, Inc. (NASDAQ:ABMD). Brown Cap Management Lc owns 1.39 million shares. Texas Permanent School Fund owns 30,587 shares for 0.07% of their portfolio. Duncker Streett & has 350 shares for 0.02% of their portfolio. Stifel Fincl holds 3,027 shares or 0% of its portfolio. Cap Fund Mgmt reported 0.02% in ABIOMED, Inc. (NASDAQ:ABMD). Gilder Gagnon Howe And Company Ltd Liability Corporation owns 15,048 shares or 0.04% of their US portfolio. Dorsey Wright & Associates holds 1.08% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD) for 27,772 shares. 99,652 were reported by Country Comml Bank. Gemmer Asset Management Limited Liability has 0% invested in ABIOMED, Inc. (NASDAQ:ABMD). 13,893 were accumulated by Bnp Paribas Arbitrage. Lpl Limited Co reported 13,802 shares. First Advsr Ltd Partnership accumulated 0.05% or 116,867 shares. Eagle Asset invested 0.23% of its portfolio in ABIOMED, Inc. (NASDAQ:ABMD). 1.98M are held by Baillie Gifford And Company.

Since September 30, 2017, it had 0 insider purchases, and 2 sales for $7.32 million activity.

The stock of Abiomed Inc (NASDAQ:ABMD) registered a decrease of 10.39% in short interest. ABMD’s total short interest was 881,900 shares in March as published by FINRA. Its down 10.39% from 984,200 shares, reported previously. With 333,700 shares average volume, it will take short sellers 3 days to cover their ABMD’s short positions. The short interest to Abiomed Inc’s float is 2.03%.

The stock decreased 0.66% or $1.95 during the last trading session, reaching $292.62. About 256,730 shares traded. ABIOMED, Inc. (NASDAQ:ABMD) has risen 40.97% since March 16, 2017 and is uptrending. It has outperformed by 24.27% the S&P500.

ABIOMED, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. The company has market cap of $12.96 billion. It also provides continuum of care to heart failure patients. It has a 146.82 P/E ratio. The firm offers Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; Impella CP that provides partial circulatory support using an extracorporeal bypass control unit; Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; and Impella RP, a percutaneous catheter axial flow pump.

ABIOMED, Inc. (NASDAQ:ABMD) Ratings Coverage

Among 14 analysts covering Abiomed (NASDAQ:ABMD), 11 have Buy rating, 0 Sell and 3 Hold. Therefore 79% are positive. Abiomed had 33 analyst reports since August 4, 2015 according to SRatingsIntel. The stock of ABIOMED, Inc. (NASDAQ:ABMD) has “Outperform” rating given on Wednesday, May 4 by Leerink Swann. On Tuesday, August 4 the stock rating was maintained by BTIG Research with “Hold”. The firm has “Neutral” rating given on Monday, October 16 by BTIG Research. As per Thursday, November 2, the company rating was maintained by Jefferies. The stock of ABIOMED, Inc. (NASDAQ:ABMD) earned “Buy” rating by Jefferies on Thursday, September 21. Guggenheim maintained it with “Buy” rating and $280.0 target in Friday, February 2 report. Jefferies maintained the stock with “Buy” rating in Tuesday, August 9 report. Jefferies maintained it with “Buy” rating and $220.0 target in Thursday, December 21 report. Benchmark maintained the stock with “Buy” rating in Tuesday, August 4 report. Morgan Stanley maintained the shares of ABMD in report on Friday, February 2 with “Equal-Weight” rating.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.